Articles From: Grupo Simec, S.A.B. de C.V. announces repurchases of its own shares to Guaranty Bancorp Announces 2014 First Quarter Financial Results


2014/4/25
GUADALAJARA, Mexico, April 25, 2014 /PRNewswire/ -- Grupo Simec , S.A.B de C.V. (NYSE: SIM) announces to the general public that through its repurchase fund, on April 24, 2014 , bought 28,196 of its own shares, (SIMEC-B). Grupo Simec S.A.B de C.V. has authorized a repurchase fund of $ 1,000 million pesos, which will be used to support interested investors in generating greater liquidity of its stock in the market, buying stocks when needed and selling them when there is excess of demand.
Sign-up for Grupo Simec, S.A.B. de C.V. announces repurchases of its own shares investment picks
2014/4/24
GUADALAJARA, Mexico , April 24, 2014 /PRNewswire/ -- Grupo Simec , S.A.B de C.V. (NYSE: SIM) announces to the general public that through its repurchase fund, on April 23, 2014 , bought 43,824 of its own shares, (SIMEC-B). Grupo Simec , S.A.B de C.V. has authorized a repurchase fund of $ 1,000 million pesos, which will be used to support interested investors in generating greater liquidity of its stock in the market, buying stocks when needed and selling them when there is excess of demand.
Sign-up for Grupo Simec, S.A.B. de C.V. announces repurchases of its own shares investment picks
2014/5/8
GUADALAJARA, Mexico , May 8, 2014 /PRNewswire/ -- Grupo Simec , S.A.B. de C.V. (NYSE: SIM) announces to the general public that through its repurchase fund, on May 07, 2014 , bought 335,000 of its own shares, (SIMEC-B). Grupo Simec , S.A.B. de C.V. has authorized a repurchase fund of $ 1,000 million pesos, which will be used to support interested investors in generating greater liquidity of its stock in the market, buying stocks when needed and selling them when there is excess of demand.
Sign-up for Grupo Simec, S.A.B. de C.V. announces repurchases of its own shares investment picks
2014/5/9
GUADALAJARA, Mexico , May 9 2014 /PRNewswire/ -- Grupo Simec, S.A.B de C.V. (NYSE: SIM) announces to the general public that through its repurchase fund, on May 08, 2014 , bought 475,000 of its own shares, (SIMEC-B). Grupo Simec S.A.B de C.V. has authorized a repurchase fund of $ 1,000 million pesos, which will be used to support interested investors in generating greater liquidity of its stock in the market, buying stocks when needed and selling them when there is excess of demand.
Sign-up for Grupo Simec, S.A.B. de C.V. announces repurchases of its own shares investment picks
2014/5/6
GUADALAJARA, Mexico , May 6, 2014 /PRNewswire/ -- Grupo Simec , S.A.B de C.V. (NYSE: SIM) announces to the general public that through its repurchase fund, on May 05, 2014 , bought 573,469 of its own shares, (SIMEC-B). Grupo Simec S.A.B de C.V. has authorized a repurchase fund of $ 1,000 million pesos, which will be used to support interested investors in generating greater liquidity of its stock in the market, buying stocks when needed and selling them when there is excess of demand.
Sign-up for Grupo Simec, S.A.B. de C.V. announces repurchases of its own shares investment picks
2014/5/13
GUADALAJARA, Mexico , May 13, 2014 /PRNewswire/ -- Grupo Simec , S.A.B de C.V. (NYSE: SIM) announces to the general public that through its repurchase fund, on May 12, 2014 , bought 440,000 of its own shares, (SIMEC-B). Grupo Simec S.A.B de C.V. has authorized a repurchase fund of $ 1,000 million pesos, which will be used to support interested investors in generating greater liquidity of its stock in the market, buying stocks when needed and selling them when there is excess of demand.
Sign-up for Grupo Simec, S.A.B. de C.V. announces repurchases of its own shares investment picks
2014/5/21
GUADALAJARA, Mexico, May 21, 2014 /PRNewswire/ -- Grupo Simec , S.A.B de C.V. (NYSE: SIM) announces to the general public that through its repurchase fund, on May 20, 2014 , bought 25,000 of its own shares, (SIMEC-B). Grupo Simec S.A.B de C.V. has authorized a repurchase fund of $ 1,000 million pesos, which will be used to support interested investors in generating greater liquidity of its stock in the market, buying stocks when needed and selling them when there is excess of demand.
Sign-up for Grupo Simec, S.A.B. de C.V. announces repurchases of its own shares investment picks
2014/5/20
GUADALAJARA, Mexico , May 20, 2014 /PRNewswire/ -- Grupo Simec , S.A.B de C.V. (NYSE: SIM) announces to the general public that through its repurchase fund, on May 19, 2014 , bought 475,300 of its own shares, (SIMEC-B). Grupo Simec S.A.B de C.V. has authorized a repurchase fund of $ 1,000 million pesos, which will be used to support interested investors in generating greater liquidity of its stock in the market, buying stocks when needed and selling them when there is excess of demand.
Sign-up for Grupo Simec, S.A.B. de C.V. announces repurchases of its own shares investment picks
2014/5/14
GUADALAJARA, Mexico , May 14, 2014 /PRNewswire/ -- Grupo Simec , S.A.B de C.V. (NYSE: SIM) announces to the general public that through its repurchase fund, on May 13, 2014 , bought 527,000 of its own shares, (SIMEC-B). Grupo Simec S.A.B de C.V. has authorized a repurchase fund of $ 1,000 million pesos, which will be used to support interested investors in generating greater liquidity of its stock in the market, buying stocks when needed and selling them when there is excess of demand.
Sign-up for Grupo Simec, S.A.B. de C.V. announces repurchases of its own shares investment picks
2014/5/19
GUADALAJARA, Mexico , May 19, 2014 /PRNewswire/ -- Grupo Simec , S.A.B de C.V. (NYSE: SIM) announces to the general public that through its repurchase fund, on May 16, 2014 , bought 505,000 of its own shares, (SIMEC-B). Grupo Simec S.A.B de C.V. has authorized a repurchase fund of $ 1,000 million pesos, which will be used to support interested investors in generating greater liquidity of its stock in the market, buying stocks when needed and selling them when there is excess of demand.
Sign-up for Grupo Simec, S.A.B. de C.V. announces repurchases of its own shares investment picks
2014/4/30
http://media.marketwire.com/attachments/201102/37860_grupotmmlogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1111128&ProfileId=051205&sourceType=1 MEXICO CITY, MEXICO --
Sign-up for Grupo TMM Reports First-Quarter 2014 Financial Results (in Millions of Mexican Pesos) investment picks
http://media.marketwire.com/attachments/201301/55618_gsitechnologylogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1111708&ProfileId=051205&sourceType=1 SUNNYVALE, CA --
Sign-up for GSI Technology, Inc. Reports Fourth-Quarter Fiscal 2014 Results investment picks
http://media.marketwire.com/attachments/201301/55618_gsitechnologylogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1108760&ProfileId=051205&sourceType=1 SUNNYVALE, CA --
Sign-up for GSI Technology, Inc. to Announce Fiscal 2014 Fourth-Quarter and Year End Results on May 1, 2014 investment picks
http://media.marketwire.com/attachments/201301/55618_gsitechnologylogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1115842&ProfileId=051205&sourceType=1 SUNNYVALE, CA --
Sign-up for GSI Technology, Inc. to Present at the B. Riley 15th Annual Investor Conference investment picks
Company Announcement No statistically significant difference in progression free survival in ofatumumab plus chemotherapy treatment arm compared to rituximab plus chemotherapy Detailed data will be presented at an upcoming medical conference LONDON and COPENHAGEN, Denmark, May 19, 2014 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE:GSK) and Genmab A/S (Copenhagen:GEN) announced today that the Phase III study (ORCHARRD) of ofatumumab (Arzerra(tm)) plus chemotherapy versus rituximab plus chemotherapy to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) did not meet its primary endpoint as there was no statistically significant difference in progression free survival (PFS) between the treatment arms.
Sign-up for GSK and Genmab Announce Topline Results from a Pivotal Head to Head Study of Ofatumumab in Combination With Chemotherapy vs Rituximab in Combination with Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma investment picks
Company Announcement CHMP recommends marketing authorization for Arzerra in combination with chlorambucil or bendamustine for patients with CLL who have not received prior therapy and are not eligible for fludarabine-based therapy Final decision from European Commission expected in the coming months COPENHAGEN, Denmark, May 23, 2014 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE:GSK) and Genmab A/S (Copenhagen:GEN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending a variation to the terms of the marketing authorization for Arzerra(tm) for a new indication in combination with chlorambucil or bendamustine for the treatment of patients with chronic lymphocytic leukemia (CLL) who have not received prior therapy and who are not eligible for fludarabine-based therapy.
Sign-up for GSK and Genmab Receive CHMP Positive Opinion for Arzerra(tm) in Combination with Chlorambucil or Bendamustine as a First-line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Not Eligible for Fludarabine-based Therapy investment picks
Company Announcement Arzerra now approved for use in previously untreated patients for whom fludarabine-based therapy is considered inappropriate Approval based on Phase III data from study with ofatumumab + chlorambucil COPENHAGEN, Denmark, April 17, 2014 (GLOBE NEWSWIRE) -- Copenhagen, Denmark; April 17, 2014 - GlaxoSmithKline plc (LSE:GSK) and Genmab A/S (Copenhagen:GEN) announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra (r) (ofatumumab), a CD20-directed monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.
Sign-up for GSK and Genmab Receive FDA Approval for Arzerra(r) (ofatumumab) as First-Line Treatment in Combination with Chlorambucil for Patients with Chronic Lymphocytic Leukemia (CLL) for Whom Fludarabine-Based Therapy is Considered Inappropriate investment picks
WOODSIDE, Calif., April 10, 2014 (GLOBE NEWSWIRE) -- GSV Capital Corp.
Sign-up for GSV Capital Corp. Provides Mid-Quarter Business Commentary and Update on Portfolio Company Developments investment picks
WOODSIDE, Calif., April 28, 2014 (GLOBE NEWSWIRE) -- GSV Capital Corp.
Sign-up for GSV Capital Corp. to Report First Quarter 2014 Financial Results on Thursday, May 8, 2014 investment picks
MERRIMACK, N.H., April 7, 2014 (GLOBE NEWSWIRE) -- GT Advanced Technologies (Nasdaq:GTAT) today announced that it has received $58.6 million in orders this quarter for high temperature refractory metal furnaces that are used for a variety of industrial purposes.
Sign-up for GT Advanced Technologies Announces $58.6 Million Specialty Furnace Orders investment picks
MERRIMACK, N.H., May 5, 2014 (GLOBE NEWSWIRE) -- GT Advanced Technologies (Nasdaq:GTAT) today announced that it will be making its next generation ASF®165 sapphire growth furnace, for the production of high volume and high quality sapphire material, commercially available in Q3'14.
Sign-up for GT Advanced Technologies Announces Larger Capacity ASF(R)165 Sapphire Furnace investment picks
MERRIMACK, N.H., April 17, 2014 (GLOBE NEWSWIRE) -- GT Advanced Technologies Inc. (Nasdaq:GTAT) , today announced that the company will release its financial results for the quarter ended March 29, 2014 after the market closes on NASDAQ on Wednesday, May 7, 2014.
Sign-up for GT Advanced Technologies to Host Q1FY14 Conference Call and Webcast on May 8th, 2014 investment picks
2014/5/6
DALLAS , May 6, 2014 /PRNewswire/ -- GTM Hospitality, LLC and LIG Assets, Inc. (PK: LIGA) announce the acquisition of the Wyndham Baton Rouge Hotel.
Sign-up for GTM Hospitality, LLC and LIG Assets, Inc. Announce Acquisition of the Wyndham Baton Rouge Hotel investment picks
GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on June 4, 2014, at the Jefferies 2014 Global Healthcare Conference in New York City.
Sign-up for GTx Announces Webcast of Corporate Presentation at Jefferies 2014 Global Healthcare Conference investment picks
GTx, Inc. (NASDAQ: GTXI) today announced that the timing for its first quarter 2014 financial results press release will be Thursday, May 8, 2014, prior to the opening of the U.S. stock markets.
Sign-up for GTx, Inc. To Report First Quarter 2014 Financial Results On May 8, 2014 investment picks
http://media.marketwire.com/attachments/201205/46042_Gwanweiupdatedlogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1118230&ProfileId=051205&sourceType=1 FUQING CITY, CHINA --
Sign-up for Guanwei Recycling Corp. Comments on Local News Article investment picks
http://media.marketwire.com/attachments/201205/46042_Gwanweiupdatedlogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1115777&ProfileId=051205&sourceType=1 FUQING CITY, CHINA --
Sign-up for Guanwei Recycling Corp. Reports 2014 First Quarter Results investment picks
http://media.marketwire.com/attachments/201205/46042_Gwanweiupdatedlogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1113828&ProfileId=051205&sourceType=1 FUQING CITY, CHINA --
Sign-up for Guanwei Recycling Corp. Response to Investor Questions investment picks
http://media.marketwire.com/attachments/201304/59875_LOGOguaranty.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1107449&ProfileId=051205&sourceType=1 DENVER, CO --
Sign-up for Guaranty Bancorp Announces 2014 First Quarter Financial Results investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Grupo Simec, S.A.B. de C.V. announces repurchases of its own shares to Guaranty Bancorp Announces 2014 First Quarter Financial Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry